Press coverage about BioCardia (NASDAQ:BCDA) has trended positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioCardia earned a daily sentiment score of 0.34 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3008216930955 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
BioCardia (NASDAQ:BCDA) opened at $0.41 on Wednesday.
BioCardia, Inc, formerly Tiger X Medical, Inc, is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure.
Receive News & Ratings for BioCardia Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia Inc and related companies with MarketBeat.com's FREE daily email newsletter.